News Hub | News Direct

Holiday Season Winner? This Electric Toothbrush Maker Generated Record Sales In November And Is Appearing On Home Shopping Channel TSC

Bruush Oral Care Inc.

Learn more about Brüush by downloading the latest research report here According to a survey by SurveyMonkey, about 32% of people said they spent $100-300 on holiday gifts, 29% said they spent less than $100, and 7% said they spent over $1000. The survey paints a perfect picture of the importance people attach to holiday gifts. As yuletide draws closer, these gifts are bound to be an integral part of the shopping list of customers who throng some of America’s biggest shopping outlets, such as Target Corporation (NYSE: TGT), Best Buy Co Inc. (NYSE: BBY), Amazon.com Inc. (NASDAQ: AMZN), Walmart Inc. (NYSE: WMT), Macy’s Inc. (NYSE: M) and Wayfair Inc. (NYSE: W). Interest in these holiday gifts does have a positive ripple effect on stocks of these shopping outlets, including companies like Signet Jewelers Ltd. (NYSE: SIG) and Apple Inc. (NASDAQ: AAPL), which produce holiday items such as jewelry and gadgets. The time of the year does often bring growth to sellers of gifts, and one company just saw record sales this November. The talk of stocks that perform during the festivities and choosing the perfect Christmas gift could bring to mind another company, Brüush Oral Care Inc. (NASDAQ: BRSH), a modern electric toothbrush brand looking to disrupt the oral care market. Perfect Gift This Holiday Season? What could be getting this company some attention is a recent report that it recorded more than $500,000 in revenues in November, representing year-over-year growth of over 50%. The impressive sales resulted in November 2022 being the best month in the company’s history. For many, the news may not come as a surprise considering the fact that Brüush recently revealed that its beautifully designed one-of-a-kind electric toothbrush has received more than 90% five-star review ratings with less than a 1% return rate. The electric toothbrush is built with the highest-quality Sonicare technology, four-week battery life and best-in-class prices. The company says it is determined to make the move from manual to electric a no-brainer, backed by a brush head refill subscription plan. The plan includes three new brush heads for $18 ($6 per brush head) with free shipping every six months. Exciting Times To Brüush? Currently, the company says it has over 35,000 active subscriptions in its brush head refill program, representing a 25% increase during the four-month period since going public in August 2022. “We are obviously excited about our growth since the IPO in August and that November was a record month for us. Our electric toothbrush makes a great gift, so we expect strong sales to continue through the holiday season,” Aneil Manhas, Founder and CEO of Brüush, said. The company also recently announced that it’s participation in a one-day sales campaign on the home shopping channel, Today’s Shopping Choice (“TSC”), on Friday December 16, 2022. “This will be the Company’s second appearance on the home shopping channel, with their first appearance having taken place in September. TSC is Canada’s only nationally televised shop-from-home service, reaching into over 7 million households. The Brüush electric toothbrush will be featured on TSC during three segments on Friday, December 16, which can be viewed on the TSC website ( https://tsc.ca ) and will occur at 9.30am, 1.30pm and 5.30pm (Eastern Standard Time).” About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

December 27, 2022 08:00 AM Eastern Standard Time

Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses

Organicell Regenerative Medicine, Inc.

To learn more about Organicell, download the latest research report here Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a pioneer in the Extracellular Vesicle (EV) space. They have already been developing exosome-based drug candidates for the treatment and prevention of COVID-19, Long COVID, Chronic Obstructive Pulmonary Disease (COPD), osteoarthritis, and other conditions. Its flagship product, Zofin™, is in human clinical trials. Since being FDA approved for an expanded access trial, the company has also treated 18 people with the exosome-based therapy and the results are promising with patients showing reduced inflammation and improved lung function. New Information Linking Exosomes and the Common Cold However, a possible new reason for companies like Organicell to get excited about EVs has recently been uncovered by researchers at Harvard University. “In what researchers are calling a scientific breakthrough, scientists behind a new study may have found the biological reason we get more respiratory illnesses in winter. It turns out the cold air itself damages the immune response occurring in the nose.” It seems that EVs have an absolutely crucial role in preventing germs from effectively entering and getting a foothold in the body through the nose. The body creates and uses EVs to mop up and get rid of harmful agents, but this becomes seemingly far more difficult when the temperature outside gets extra low. “In fact, that little bit of coldness in the tip of the nose was enough to take nearly 42% of the extracellular vesicles out of the fight…” One of the researchers, Dr. Benjamin Bleier, “expects to see the development of topical nasal medications that build upon this scientific revelation. These new pharmaceuticals will ‘essentially fool the nose into thinking it has just seen a virus,’ he said.” The Emerging Research On Exosomes Is Filled With Promise, But Still New While often confused with stem cells, exosomes are not cells. They are the smallest of all Extracellular Vesicles (EVs) – the various particles cells secrete to send messages and materials to each other. EVs are how cells tell each other to reproduce, differentiate into specific cells, repair, and so on. It’s also how cells pass along proteins, lipids, DNA, RNA, and other materials that the receiving cell might need to carry out those functions. EVs may have the potential to reduce inflammation, repair damaged tissue, and otherwise help cells regenerate and heal. Their ability to carry cargo to a cell has also attracted interest from biopharmaceutical developers who are looking into using EVs as a delivery mechanism for therapeutics. If these developers can engineer EVs that carry a specific drug to specific cells – like delivering chemotherapeutic agents to tumor cells – they could create more targeted treatments with fewer adverse reactions. Biotech companies are working on creating the technology necessary to reliably engineer exosomes to create potent and highly targeted treatments. This field of study is still emerging and there is a lot that researchers still don’t yet know about EVs. A lot of the most promising data to come out about these messenger particles is from animal and cell culture studies. So a major hurdle the research still needs to overcome is whether those exciting findings will translate to human studies. Organicell is among the companies to have already begun human trials for an exosome therapy. Zofin TM, its lead drug candidate, is being developed as a potential treatment for COVID, Long COVID, COPD, and osteoarthritis. Does all this mean even bigger opportunities for treatments and products for companies like Organicell? Learn more about Organicell’s research and products here. Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/

December 27, 2022 08:00 AM Eastern Standard Time

Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares

Sunshine Biopharma Inc.

To learn more about Sunshine Biopharma, download the latest research report here Sunshine Biopharma Inc. (NASDAQ: SBFM) is a fully integrated pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. On November 30th, 2022, Sunshine Biopharma’s chief financial officer (CFO) Camille Sebaaly purchased 30,000 shares at $0.7635/share for a total of $23,000. The Canadian-based company is heavily focused on eradicating the virally-driven Covid-19 pandemic. While its expansion has seemingly calmed down in the West, the SARS-CoV-2 virus has resurged in China, triggering state-sanctioned quarantine mandates. Only months ago, Sunshine Biopharma Inc. announced a $19.5 million private placement priced at the market, a funding round aimed to help the Sunshine Biopharma team achieve its mission of eradicating the pandemic and creating life-saving anti-cancer treatments. An Overview Of Sunshine Biopharma Aside from insider buying ( including another recent purchase by Sebaaly in June of 25,000 shares at $1.22 per share for a total of $30,500), Sunshine Biopharma has seen a number of potentially constructive developments in its business. These include: Pioneering a novel Covid-19 treatment method, called SBFM-PL4, that reportedly targets a different part of the virus than other treatments. Creating a flagship anticancer compound, Adva-27a, that, unlike other antitumor drugs, can destroy multi-drug-resistant cancer cells. Filing a provisional patent application in the United States about the company’s mRNA cancer treatment results, which were shown to destroy cancer cells grown in culture. Developing nutritional supplements, like Essential 9™, for sale in Canada and the U.S. on Amazon The company also completed an acquisition of Nora Pharma, a Canadian pharmaceutical company offering generic and specialty drugs across the country, which adds $10.7 million in revenue for 2022. With a focus on both oncology and antiviral drugs, Sunshine Biopharma is placing itself within two fast-growing markets. According to Bloomberg, the anti-viral drug market size is expected to reach $50 billion in 2030, and the oncology market is expected to be worth around $536 billion by 2029. Click here for more on Sunshine Biopharma. In addition to working with the University of Arizona on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a novel anticancer mRNA called K1.1. The data collected to date have shown that K1.1 mRNA is capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery into patients using the proven mRNA vaccine technology. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980 investors@sunshinebiopharma.com Company Website https://sunshinebiopharma.com/

December 27, 2022 08:00 AM Eastern Standard Time

70% Of Americans Don’t Floss - This Company Aims To Change That With Its New Engineering Approach

Instafloss

Interested in investing in Instafloss’s campaign? Click here to get started. Oral Care Is More Important Than You Think While it can be easy to neglect your oral health, an unhealthy mouth can be a precursor for an unhealthy body. The mouth is filled with both good and bad bacteria, and when the mouth, teeth, and gums are poorly taken care of, bad bacteria take over. Because the mouth is the entry point for the respiratory and digestive systems, these bacteria can then spread even further and cause disease. Individuals with poor oral health have higher risks of cardiovascular disease, heart attacks, pneumonia, and other ailments. Take cardiovascular disease - inflammation in the gums will slowly travel down the body to the arteries and increased plaque build-up can cause heart attacks. Despite these high risks, only 58% of Americans see a dentist as least once a year. Nearly 1 million Americans visit the emergency room each year because of dental pain, according to a Pew study. Oral health, or rather the lack of oral health, can have catastrophic effects on the body. The long-lasting effects of poor oral care are why it is so important for individuals to have a strong oral care routine and tools at home to maintain a healthy mouth, teeth, and gums. Instafloss Has Engineered What Could Be A Perfect Solution Currently, there are two options available on the market when it comes to flossing: standard floss and manual 1-jet water flossing. Both options can be time-consuming, cumbersome and painful and as a result, 70% of Americans do not floss. Furthermore, individuals who do floss often do it ineffectively. Individuals deserve better options for flossing that promote oral health. That’s why Instafloss developed its multi-jet water flosser. Instafloss’s design aims all the jets for the user at the correct 90-degree angle, ensuring that the teeth and gums are fully covered. It only takes 10 seconds to sweep across the teeth and Instafloss uses a patented H-design mouthpiece that fits over the top and bottom teeth. Instafloss is able to clean between your teeth, underneath your gum line, and all the way around each tooth for maximum coverage. Water flossing could be the way of the future. When compared to string flossing, water flossing is 151% as effective at reducing gingivitis, 129% as effective at removing plaque, and 200% as effective at reducing bleeding, according to research cited on the Instafloss website. Instafloss is currently hosting a raise on Republic to propel the company forward. The company has over $2.5 million in pre-orders with another 41,000 individuals on an email waitlist. To date, they have raised over $950k in equity capital. With 5 years of testing and granted utility patents, the company is ready to become the next big thing in oral care. Click here to read more about Instafloss’s raise and how to invest. Instafloss is the world’s first 10 second floss. It is painless, effective, and fast — removing obstacles to oral health. Contact Details Eli Packouz eli@instafloss.com Company Website https://instafloss.com/

December 27, 2022 08:00 AM Eastern Standard Time

Precigen’s Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy

Precigen, Inc.

Acute myeloid leukemia (AML) is among the most common types of leukemia in adults. The term leukemia refers to cancers of the bone marrow and blood cells. Doctors refer to AML as “acute” because the condition is known to progress rapidly. The five-year survival rate for patients with AML is as low as 5%, leading to approximately 11,000 deaths annually in the US. Each year sees 20,000 newly diagnosed cases of AML and, after initial treatments, roughly 50% relapse with a very poor prognosis. Precigen Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of novel gene and cell therapies, has developed a ground-breaking technology that enables the treatment of AML using targeted CAR-T therapy administered overnight right at the facility where a patient is being treated. In some cancers, such as advanced AML, even a day’s delay in treatment could make a difference in survival. The main treatment for most types of AML is currently chemotherapy, which has been the mainstay of treatment for various types of cancers for decades. But over the past several years, the U.S. Food and Drug Administration (FDA) has approved new categories of cancer medicines – among them CAR-T – which are transforming the treatment picture of certain cancers effectively, and in some cases helping to stave off cancer for many years. CAR-T Therapy Developed By Precigen Could Potentially Be A Promising First In The Treatment Of AML AML progresses very rapidly, making it essential to treat it as quickly as possible. Because of this, autologous CAR-T therapy, which usually takes 3-4 weeks to manufacture for each patient, has not been successful in treating patients with advanced AML. The current process for making autologous CAR-T therapy involves multiple, time-consuming and costly steps that include drawing patient blood, transporting it to a central manufacturing facility, transfecting the patient’s T cells with a lentivirus for antigen targeting, and expanding the cells for weeks in the lab before shipping the therapy back for infusion into the patient. T cells, a key component of the immune system, help the body fight infection and tumors. In contrast, Precigen’s technology condenses this time-consuming process into overnight manufacturing using the patient's own cells to make its UltraCAR-T cells. This is made possible by using the company’s patented UltraPorator ®, a custom manufacturing device, designed for decentralized use to enable UltraCAR-T to be made and administered in any hospital where the patient is being treated. Precigen is conducting a Phase 1b clinical trial of its PRGN-3006 UltraCAR-T in patients with advanced AML who have failed multiple prior therapies. The company released encouraging clinical data last year, raising hopes that PRGN-3006 could prove to be a significant new treatment choice for relapsed or refractory AML patients who have run out of other options. Updated data presented earlier this month at the 64 th Annual Meeting and Exposition of the American Society of Hematology showed that a single infusion of UltraCAR-T cells following lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow and resulted in a 27 percent objective response rate (ORR) is heavily pre-treated r/r AML patients. David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffit Cancer Center and Research Institute, and a lead investigator for the PRGN-3006 clinical trial, said a 27 percent ORR in this patient population, which has limited treatment options, is a significant result. He reported PRGN-3006 has an excellent safety profile with no drug-limiting toxicities observed to date, and noted that a patient who received PRGN-3006 following allo-HSCT has responded to treatment for more than 18 months. The success of its clinical trials could establish the viability of reducing the processing time of autologous CAR-T therapy for AML from weeks to overnight – a time advantage that could save lives at a significantly lower cost. Combining The Best Of Autologous And Allogenic CAR-T technology For Optimum Results? There are two forms of CAR-T (chimeric antigen receptor T cell) technology. One is autologous (custom-made for each patient with the patient's own cells), and the other is allogenic (made with donor-sourced cells and packaged as an off-the-shelf product). The current market for autologous CAR-T therapy comprises key players including Gilead Sciences, Inc. (NASDAQ: GILD), Bristol-Myers Squibb Co. (NYSE: BMY), Novartis AG (SWX: NOVN) and Johnson & Johnson (NYSE: JNJ). Although autologous CAR-T has a record of good outcomes, its high cost and prolonged time to manufacture (up to 28 days) have been seen as major drawbacks. Clinical trials of off-the-shelf allogenic CAR-T have been met with limited success so far. The drawbacks of allogenic CAR-T include reduced durability of response and potential issues relating to the rejection of the donated graft by the patient (graft vs host disease), which could prove to be treatment-limiting and outweigh the potential cost and convenience benefits of this type of treatment. Companies developing allogeneic CAR-T include Allogene Therapeutics Inc. (NASDAQ: ALLO), Crispr Therapeutics AG (NASDAQ: CRSP), Editas Medicine Inc. (NASDAQ: EDIT) and Caribou Biosciences Inc. (NASDAQ: CRBU). The Precigen approach seeks to combine the efficacy and safety of autologous CAR-T with the potentially lower cost and convenience of allogenic CAR-T. Precigen’s UltraCAR-T is a platform technology, potentially adaptable to the treatment of many different cancers, in both liquid and solid tumors. Other UltraCAR-T candidates in development include PRGN-3005 for recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, and PRGN-3007 for treating a variety of cancers, including chronic lymphocytic leukemia, mantle cell leukemia, acute lymphocytic leukemia and triple-negative breast cancer. The company also reports that PRGN-3006 UltraCAR-T has demonstrated a favorable safety profile to date with no dose-limiting toxicities or neurotoxicity. PRGN-3006 has also received orphan drug designation and fast track status from the FDA. "We are very pleased to receive the FDA's Fast Track designation, which facilitates development and expedites the review process of drugs that address serious conditions and high unmet medical needs," says Helen Sabzevari, PhD, President and CEO of Precigen. Dr. Sabzevari added, "AML is a rapidly progressing disease with a very poor prognosis. The Fast Track designation will help facilitate the timely development of this program and we look forward to working closely with the FDA to potentially bring this new and highly differentiated overnight UltraCAR-T therapy to patients." Click here for more information about Precigen, Inc. (PGEN) This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Photo by National Cancer Institute on Unsplash Precigen: Advancing Medicine with Precision™Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologiesenable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Contact Details Steven M. Harasym sharasym@precigen.com Company Website https://precigen.com/

December 27, 2022 08:00 AM Eastern Standard Time

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

Can-Fite Biopharma

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson’s high efficacy and good safety record with anti-inflammatory and anti-cancer effects — in line with Phase II and Phase III studies conducted by the company. Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5’- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). According to Can-Fite, the drug has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation and in a Phase IIa NASH study. Interestingly, Namodenoson is not the only drug in the company’s pipeline that seems to be grabbing a lot of attention. Can-Fite is also conducting studies for Piclidenoson for treating psoriasis and CF602 for treating erectile dysfunction. Can-Fite seems to have carved a niche for itself as an advanced clinical-stage drug development company with a platform technology designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. Multiple Shots On Goal The company’s lead drug candidate, Piclidenoson, recently reported topline results in a Phase III trial for psoriasis. Namodenoson is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, is open for enrollment. The drug has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second-line treatment for HCC by the U.S. Food and Drug Administration. Can-Fite says Namodenoson has shown proof of concept to potentially treat other cancers, including colon, prostate, and melanoma. The company’s third drug candidate, CF602, reports suggest, has also shown efficacy in treating erectile dysfunction. These drugs, according to Can-Fite, have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. Late-Stage Clinical Development Pipeline The company’s late-stage clinical pipeline seems to be ticking all the right boxes. For example, Can-Fite recently reported that if the Phase III pivotal (registration) study for liver cancer meets its primary endpoint, then Namodenoson can be approved to treat it. The Phase III pivotal (registration) study for psoriasis, it added, is now being prepared based on successful results from the most recent Phase III study of Piclidenoson, which showed the drug is safe and effective. Lastly, the Phase IIb NASH study is now enrolling and treating patients, following a successful Phase IIa study. Clearance Of Cancer In Patients Treated With Namodenoson? On October 25, the company reported that a patient, a 61-year-old woman with hepatocellular carcinoma (HCC), the most common form of liver cancer, and moderate hepatic dysfunction Child-Pugh B (CPB7), participated in Can-Fite’s prior Phase II study. The patient was in the Namodenoson arm of the Phase II study and continued treatment with Namodenoson for five years under an Open Label Extension Program. Treatment is ongoing under a Compassionate Use Program established in Romania in August of 2022. This case report demonstrates that treatment with Namodenoson can lead to a complete and durable response in patients with HCC and CPB7. Current Out-Licensing Deals Can-Fite has out-licensed its drugs to companies such as Cipher Pharmaceuticals Inc. (TSE: CPH) (Canada), China Medical System Holdings (HKG: 0867) (China), Kyongbo Pharmaceutical Co Ltd. (KRX: 214390) (South Korea), Gebro Pharma (Spain, Austria, and Switzerland), and Ewopharma (Central Eastern Europe). The company has already received $20 million in upfront and milestone payments and expects $130 million in revenues based on regulatory and sales milestones. About Can-Fite BioPharma Ltd.Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment is expected to commence in a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Forward-Looking StatementsThis press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 24, 2022 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Details Motti Farbstein Motti@canfite.co.il Company Website https://www.canfite.com

December 27, 2022 08:00 AM Eastern Standard Time

Applied UV Announces $5 Million Secured Revolving Credit Facility

Applied UV, Inc.

Applied UV, Inc. (NASDAQ: AUVI), a pathogen elimination technology company, announced a $5 million secured revolving credit facility effective December 8, 2022. Borrowings under the revolving credit facility will be used for general corporate purposes and to advance Applied UV’s organic and strategic growth initiatives. The facility currently has no outstanding balance. Max Munn, Applied UV, Inc.’s President and Founder, said: "This facility further bolsters our near-term liquidity position and provides us with additional flexibility to execute our growth strategy including the timely delivery of products from an increasing backlog of orders in our hospitality business. Over the past few weeks, we have increased capital availability by $7.5 million with the closing of this new revolver and $2.5 million in an unsecured loan earlier this month. We are taking the steps necessary to ensure we have access to capital to support an acceleration in sales and deliver positive cash flow." Additional details regarding the credit facility are available in a Current Report on the Form 8-K filed with the Securities and Exchange Commission. About Applied UV Applied UV, Inc. ("AUVI") develops and acquires proprietary infection prevention and control technology in the healthcare, commercial & public venue, food processing/storage, cannabis, and education, vertical markets. The company has two wholly owned subsidiaries - SteriLumen, Inc. and Munn Works, LLC. Sterilumen owns and markets a portfolio of products with advanced pathogen elimination technology, branded Airocide® by Sterilumen, Scientific Air™ by Sterilumen, Airoclean™ 420 by Sterilumen, and Lumicide™ by Sterilumen. Leading organizations globally rely on AUVI’s air purification systems to completely eliminate airborne and surface infections, mold, bacteria, allergens and other contaminants. Their customers include Kaiser Permanente, NY Health+Hospitals, Baptist Health South Florida, Boston Red Sox’s Fenway Park, JetBlue Park, France’s Palace of Versailles, Invited Clubs, Whole Foods, Del Monte Foods, U.S. Department of Veterans Affairs and more. NASA used Airocide’s and Airoclean™ 420’s Photocatalytic Oxidation technology to sanitize its International Space Station. Scientifically proven to reduce Healthcare Acquired Infections (HAI), Scientific Air™ offers a proprietary 3-stage technology integrating HEPA filters, ultraviolet germicidal light chamber and active carbon substrate. For information on Applied UV, Inc., and its subsidiaries, please visit the following websites: https://applieduvinc.com/, https://sterilumen.com/ and https://airoclean420.com/. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

December 27, 2022 08:00 AM Eastern Standard Time

News Release

7 Best Essay Writing Services 2023: Legit Paper Writing Websites

Writing Solutions

Are you looking for a professional essay writing service that delivers quality content reliably? If so, you are not alone. Many people are choosing to buy essay writing services, especially as more people attend university or college and realize they simply don’t have time to get everything done. There are many reasons to use these types of services. You might be too busy with final exams or work to get your essays done on time. Using an essay writing service can actually save you time, energy and mental strength for more important ventures, like work. You can also use these services to help give you a better idea of what a great essay on a certain subject looks like, so that you can improve your own writing in the future. Or you can use these services for essays in unimportant subjects, so that you can redirect your primary focus towards your major. Regardless of why you want someone to write your essay, there is one hard truth to face: it can be surprisingly hard to find the best essay writing service. Some companies delivery poor quality results, don’t cover the subject you need, or they don’t even deliver at all and scam you out of your money. How do you tell the “dud” companies from the professional companies? Look no further than this guide. We understand how hard it is to find a great essay writing service, which is why we’ve prepared this guide to the best essay writing services that you’ll find today. These are reliable, legitimate websites that will deliver quality results on time, every time. If you’re ready to take some weight off your academic shoulders, take a look at the following guide that will help you find writing services to suit your needs in 2023. Looking for a quick fix? Here is our top 7 list. 99Papers - the absolute best essay writing service to use in 2023. PaperHelp - a highly rated writing company based in the USA. 1Essay - professional college paper writers to hire Studdit - newest website with TOP writers EssayPro - cheap essay writing company EssayBox - one of the best website to buy essays online MyAdmissionEssay - write my admission essay provider. Ready to find out more about these great services? Read on to explore their reviews! The List of 7 Best Essay Writing Services 2022/23 1. 99Papers 99Papers is the top essay writing service out there today. They provide customizable essay writing services and a money back guarantee that will make you feel at ease about buying essays from them. Features 99Papers features a 100% money-back guarantee if you're not satisfied with your essay, along with a plagarism-free guarantee. 99Papers uses special software to detect plagiarism. This is especially critical in today’s digital world. How it Works 99Papers is very easy to use. First, you provide the website with the basic information about your essay: what type of essay it is (such as academic essay versus general essay); the academic level; the deadline; and how many pages the essay needs to be. 99Papers estimates 275 words per page, so keep this in mind. Once you provide the service with this information, they will get back to you with a confirmation of the price for your content. If you want to move forward, you can pay and the order will start. If you’d like, you can talk to the writer assigned to your essay. This will help you to make sure that the writer understands what you need from your essay. They can even provide you with an outline of the work. The final draft of the essay will be sent to you for approval before the deadline. Once you accept it, you can download it. Pricing 99Papers pricing will vary depending on factors like the type of essay; academic level; deadline; and page number. Their high school level essay writing starts at $9.95 per page for essays due in more than 15 days; and goes all the way to $55.50 per page for PhD level writing that is due within 3 hours. The website provides a handy chart and pricing calculator that is easy to use. From January 2023 you can use promo code D1HV77R8 to get 5% discount on your order. 99Papers Customer Review "I chose 99Papers to write my essay because of the good reviews I found online. I really liked how customized the entire process was, and the fact that I could talk to the writer who was working on my essay. I let them know about a few stylistic things I’d like in my essay, and they were accommodating for that. I also liked that I didn’t feel blindsided by the essay quality. I got an outline and approved it, and got to approve the final draft. I was worried I might need to request a refund because I’d never used them before, but the quality was great!" 2. PaperHelp PaperHelp is a top essay writing service company in the United States with plenty of features. Features PaperHelp has some unique features. These include optional paid extras that can improve your experience. Their optional extras included: VIP customer support; #1 priority in customer support and fast feedback; Plagiarism report; a report proving that the paper does not contained plagiarism; Abstract page; an abstract for content that requires it; Sources; a report providing sources used for the essay; Outline or table of contents; formatted TOC or outline for the essay; Editor checking; extra proofreading from an expert editor; Charts; charts and graphics; Writer category; choosing a writer from PaperHelp's writing categories, Basic, Advanced and TOP. How it Works The PaperHelp order process is straightforward. You provide the service with information using their provided form, which requires you to tell them the type of paper, page number, and deadline. You must also explain the essay's requirements with as much detail as possible. Then, you submit this information with a valid email. Your email will be used to log into the website, and you can pay from there. Then, you can track and manage your order using the website or app. Pricing PaperHelp's pricing will vary depending on a few factors, including the deadline, academic level, and pages required for the essay. Pricing starts at $10 per page for high school writing and a minimum $21 per page for professional writing. Best price you can get at February 2023 with Happy New Year discount codes from the service main page. One unique element of PaperHelp's pricing is that you can choose between three different types of writers, which can also influence the price. Basic writers are standard writers. Advanced writers are native English writers who are considered the top in a particular field. And TOP writers are native English writers who have the best ratings. The optional features explained above are also available for an additional cost. For instance, the VIP customer support extra is an additional $14.99. PaperHelp Customer Review "I was nervous about having an essay writing on a complex topic, but I decided to give PaperHelp a try. Overall, I was really impressed. I felt their prices were fair, especially considering the complex nature of my essay. It was delivered on time. I really liked that there was an app I could use to keep track of my order, it made things a lot easier. I found out you actually get discounts for using their service more than once, and since I was satisfied with my essay, I’ll definitely be going back for more in the future." 3. 1Essay 1Essay is a quality essay writing company known for providing more affordable essays compared to its counterparts. Features 1Essay does not have a lot of frills, but this is reflected in the affordable pricing. Their primary features include customer service support that is available 24 hours a day, seven days a week. Customer service can provide you with updates on your order or help you with anything you need. Other features include profiles of the writers which can provide you with credentials. These are available upon request only. How it Works Ordering from 1Essay simple. First, you fill out their inquiry form on their website. This form asks you to clarify the type of essay, the academic level, and the deadline. After you send in this inquiry, you can provide additional information so that the website service can confirm a price quote for you. You can connect with the writer at anytime, in case you wanna check with the progress of your essay or to provide some additional information such as notes or stylistic choices. Your essay will then be delivered before the deadline so that you can approve it and to make sure you will have it in time period in time. Pricing 1Essay’s pricing starts at $9 per page for high school writing and a minimum of $25 for PhD level writing. The pricing will vary depending on the deadline; it might also vary depending on the type of essay and topic. 1Essay Customer Review "I was a bit nervous because there weren't many features that I am used to seeing on other writing service websites. However, the S I received was really great quality, especially considering the price was blower. Despite the lower price, the writing was really high quality and professional. I felt the writer really understood the subject and the assignment." 4. Studdit Studdit is a homework help website that includes essay writing services. Features The most unique feature of this website is the ability to use free revisions. These will ensure that your SA meets your needs even before it is finished. They also provide rush services for an additional fee, for those days when you need an essay done fast. How it Works Ordering an essay from this website is fairly straightforward. First, use the order inquiry form to provide the website with essential information about your essay. This includes the academic level, the deadline and the page number. Keep in mind that your final quote may be different depending on any extras you order or the overall complexity of your essay. You can check on your order while it is being written and processed. You get at least one free revision with your purchase price. Once it is approved, you can download it. Don’t forget to rate your writer afterwards. If you like the writer, you can even add them to your favourites. Pricing Studdit’s pricing starts at $10 per page for high school writing and $21 per page for professional writing, or writing for Master’s Degree and higher. The closer the deadline, the higher the price. Studdit Customer Review "Studdit was really helpful in getting my essay done on time and professionally. Even though the topic was difficult, I feel like the writer did enough research to make it sound well-researched and thought out. I also liked that it was delivered on time, so I didn't have to worry about it being late. The website was easy to use and when I reached out to customer service for some help, I got a fast reply." 5. EssayPro EssayPro is the cheapest essay writing service with dedicated writers and great customer service. Features This service offers a few additional features, such as optional plagiarism reports for an additional fee. The most notable feature is the ability to choose the writer you want for your essay. After you choose a writer, you make a payment deposit. You only finish payment after your essay has been finished and approved. How it Works Using the services simple. First, you need to provide them with the basic information about the essay you need written. This includes the deadline, page number as well as the academic level period from there, your order inquiry will be approved with a final price quote. Then, you choose your writer and make a payment deposit. Once the essay is finished and you have approved it, you can download it for your use. You can always contact customer service during the order. If you have any questions. Pricing EssayPro’s writing starts from $10.80 per page. The pricing can vary considerably depending on the academic level, topic and deadline. EssayPro Customer Review "The best writing service I’ve used. I really liked how simple the order process was, because I didn’t have time to fuss around. The prices were fair, especially considering the high quality of the essay I received. I really feel that this service employs the best professional writers, even on niche topics that are somewhat difficult to understand." 6. EssayBox EssayBox provides quality essays at affordable prices. Features EssayBox has several unique features. One of the services most unique features is its originality reports. These reports ensure that your essay is original and won’t be considered plagiarism. Other features including free title pages, free outlines, free bibliographies, and free revisions. How it Works First, you provide the service with the basic information about the essay you need written. This includes academic level, deadline and page count. Once they have approved this information, you’ll be provided with a confirmed price quote. If you would like to move forward, make your payment and a writer will start working on your essay as soon as possible. You can check on the content while it is being written, and request revisions during or after the essay is finished so that it meets your needs. Pricing Prices start at $12 per page for high school writing or $28per page for PhD writing; this is within 15 day+ deadlines. Promo code F96MZSFW for 5% will be valid from March to May 2023. EssayBox Customer Review "Wow! I can’t believe how quickly they got my essay done. I’m so glad I chose the service, because I was really in a pinch. Not only did they get my essay to me on time, but it was well written and exactly what I needed. I will definitely use their services in the future, especially if I have something that needs to be done quickly. I also appreciated how prompt their customer service was when I reached out with my inquiry." 7. MyAdmissionEssay MyAdmissionEssay is a writing service that specializes in admission’s essays. Features In addition to regular writing services, the service specializes in admissions essays. Their features include a loyalty program that can provide you with bonuses and discounts, along with the ability to choose writers in different categories. How it Works First, you provide the service with the basic information about your essay or admissions essay. Then, you’ll be provided with a firm price quote. If you move forward, you can contact the writer you choose during the writing process to ensure that you are on the same page. After the essay is finished, and you approve it, you can download it for your use. Pricing Pricing for admissions essays starts at $20 per page for essays due in 20 days or longer. Pricing for regular essays starts at $11 per page for high school and $19 per page for professional. MyAdmissionEssay Customer Review "I use them for my admissions essay and I couldn’t be happier. They delivered it on time and I felt that the ability to choose a more professional writer helped me to get better content overall." Frequently Asked Questions The following are the most frequently asked questions about getting an essay written. How much does it cost to buy an essay online? If you tell an essay writing service, simply, “I want you to write my essay, what is your price?” then you’re not likely to get a clear answer. The reason for this is because the cost of getting an essay written online can vary depending on numerous factors. The most important factors to consider are: academic level, amount of pages, and deadline. The higher the academic level - think high school to postgraduate - the higher the price. This is because it takes more experienced, professional and knowledgeable writers to create content for college-level topics than writing intended for a high school essay. Most essay writing services will price their essays “per page,” meaning you need to multiply the page count by this price. For instance, if a service charges $10 per page for a high school essay and the essay needs to be 8 pages, the price would be $80 as a base rate. Finally, you need to consider the deadline. The sooner you need your essay delivered, the more it is going to cost due to the rush service. The amount that a company charges for a rush service will vary on the company and how quickly you need the essay. As a general rule, expect to spend anywhere from $10 to $50 per page for an essay, with the above factors in mind. Are essay writing services legitimate in the United States in 2023? They can be. The key to ensuring that the essay writing service that you’re using is legitimate is to do some research. Only purchase from websites with authentic reviews, and always look up the company on several websites to make sure that it’s legitimate. Of course, the top 7 writing services that we’ve listed are all known for providing legitimate work. But if you do decide to venture to other services, especially newer ones, it’s important to do some research in order to avoid being scammed. There are several things to consider when you are trying to decide if a writing service is legitimate. First, how new is the service? If it’s not established, you’ll have to try harder to find out information or to look for reviews. Always take a look at the legitimate reviews posted outside of the website, such as on social media or independent blogs. What do these buyers say? People are more likely to be honest with reviews when they’re posted outside the service’s website. Another thing to consider is the overall clarity of the website. Does the service offer information about who they are, why they are qualified to write essays, and what prices they charge? If so, they are more likely to be legitimate. What are the simple steps to order an essay online? It can be daunting to order a written essay online, but once you understand the process that most of these writing services use, you’ll be an expert in no time. The first thing you need to do is gather all of the information about the essay you need written. This includes the academic level, the topic, the page number, and the deadline. You should also keep any special requirements handy. For instance, if your essay needs to be written in a certain format, this is information the website service will need to know. Next, you’ll need to choose the essay writing service you want to order from; ideally, consider one of the top 7 services we’ve listed and reviewed, as these are the best options for essay writing in 2023. Then, contact the writing service through their ordering page. This may involve submitting a form or otherwise providing the service with the necessary information. Once you’re on the website’s checkout page, you can confirm the total cost and make your payment. After that, all you need to do is wait for your essay to be written and delivered. It should be noted that you should keep an eye on the email you used for this order, just in case the writing service needs additional information to complete your essay. What is the best essay writing service in 2023? 99Papers is the best essay writing service to use in 2023. They have experienced, professional writers who work with you to ensure that your essay meets the criteria that you need. Although other services may still provide quality content, if you’re looking for the best of the best, then this is the company you should choose. A highly customizable process helps to ensure that you match with a writer who can deliver a high quality essay on time period their pricing may be a bit higher than some of the other services, but the high quality you receive is well worth the trade off. Another great element of 99Papers is the fact that they have a money back guarantee. This can help ease your mind if you are worried about the quality of the essay you will receive. In addition to this, there are plagiarism detector will make sure that your essay features no plagiarism and is authentically written. If you are looking for an essay writing service that truly has it all, you can do no better than 99Papers. Quality essays, reliable service, and a very customizable order experience all help this website to stand out from the rest. What is the best website to hire college paper writer in USA? PapersHelp is the best website to hire a college paper writer based in the USA. Their content is high quality, delivered on time and they understand the college essay writing process better than many other services. When you are looking to hire an essay writing service, it is critical that you choose someone who knows what they are doing. The features offered by the service also make it an exceptional choice when it comes to getting a college essay written. If you were looking for an essay writing service that specializes in college essay writing, while also being based in the USA, this is the best option. What is the cheapest essay writing company worldwide? EssayPro is the cheapest option when it comes to essay writing. If you’re looking for an essay writer that provides quality content without breaking the bank, then this is an excellent choice. Although they don’t offer as many frills as other essay writing services, they still provide quality content that is delivered on time. If you were looking for an essay writing service that offers great content that meets your needs, this is definitely the most affordable option. Remember, you won’t be getting as many features as you would with other websites, but this is the trade off for paying less money overall. U.S. colleges with the hardest requirements for an essay writing Every college or university has different requirements when it comes to essay writing for their students. Some colleges place hardly no emphasis on essay writing at all, while others have difficult requirements that can put a lot of pressure on students to perform well in their essays. The following are the top U.S. colleges with the hardest requirements for essay writing in 2023, along with a note about what makes them so hard. University of Michigan University of Michigan requires a total of 4 admissions essays, including 3 supplementary essays. These essays are known for their tough questions. University of Notre Dame The University of Notre Dame requires a total of 4 admission essays, including 3 supplemental essays with difficult, often philosophical questions. Amherst College Amherst College is known for its rigorous admission essay requirements; the essay prompts are based on quotes provided by previous or existing Amherst students. Applications can also choose to submit exceptional, existing graded papers from previous schooling. Brown University Brown requires 4 admissions essays that involve research and intimate knowledge of Brown University. Tufts University Tufts has difficult but creative admission essays that are challenging to applicants. California Institute of Technology CIT requires a total of 8 admissions essays with diverse, engaging but tough prompts. Massachusetts Institute of Technology MIT requires applications to complete a total of 5 admissions essays that require research and thoughtful consideration. University of Chicago The University of Chicago is known for requiring 3 supplemental essays with very creative prompts that can be difficult to answer. Princeton University Princeton will require four essays, including a regular admissions essay. The prompts are often personal, while requiring deep thought. Stanford University Stanford University has a very rigorous application process which requires numerous tests, transcripts, and reports. They also require a total of 11 supplemental admissions essays with creative, engaging but very challenging prompts. The high number of essays, along with the additional application requirements, is largely what makes Stanford’s essay requirements so difficult. Final Thoughts There are many reasons why you might choose to use an essay writing service. You might need help with a difficult topic or an admissions essay; you could be swamped from work and need someone else to take the weight off your shoulders; or you simply want to buy an essay because you don’t feel like writing your essay at the moment. Whatever your reason for wanting to find the best essay writing service, it’s important to keep a few things in mind. One, if at all possible, use one of the services discussed in the article above. These websites provide the best services at reasonable rates, and you’ll find that they are highly reliable and will meet your needs every time. Two, make sure you have all of your essay information ready before you start comparing prices across the different services. This will make it easier to input your information to get a price quote, and you’ll spend less time trying to find information like your page count or requirements. Three, remember that you’ll need to pay more money for different types of writing. Buying an essay intended for high school is going to cost you less than an essay for college or a post-graduate level; the pricing can also be impacted by when you need it by, as well as the page count. Finally, remember to always do your research before you commit to purchasing an essay from any essay writing service. When you do roper research, you’ll be able to eliminate sketchy websites that deliver low quality results--or don’t deliver at all. For best results, stick with experienced, legitimate websites that have great reviews and employ professional writers that know what they’re doing. We highly recommend that, if you’re ready to buy an essay, you should strongly consider using one of the top 7 best essay writing service companies updated in December 2022 and listed above for using in the next year. Contact Details Will Collins contact@legitwritingservice.com Company Website https://legitwritingservice.com

December 22, 2022 06:02 PM Eastern Standard Time

Roberts & Ryan Inc. is pleased to announce our selection into Northern Trust Asset Management’s 2023 Minority Broker Program

Roberts & Ryan Investments, Inc.

America’s first Service-Disabled Veteran-Owned broker-dealer, Roberts and Ryan, is pleased to be selected into Northern Trust Asset Management’s 2023 Minority Broker Program. NTAM, with its long-standing commitment to ensuring diversity and inclusion within the investment industry, has expanded the program from eleven firms in 2019 to sixteen in 2023. “We look forward to working with both the new and returning member firms of our Minority Brokerage Program,” Northern Trust Asset Management’s Chief Investment Officer Angelo Manioudakis said. “The application and selection process are quite rigorous, so we have complete confidence that chosen firms will provide the high level of service for which clients have been turning to NTAM for decades.” “Roberts & Ryan is very appreciative of NTAM’s support for selecting us into their Minority Broker Program, and we are excited to work with them,”, Roberts and Ryan’s CEO, Ed D’Alessandro, said. “We are proud to have developed our services to the level where organizations like NTAM see value. We are extremely grateful for their commitment to diversity and inclusion.” About Roberts and Ryan Investments, Inc. Roberts & Ryan Investments, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over one million dollars in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. Contact Details Joe Pecoraro +1 917-658-8945 jpecoraro@roberts-ryan.com Company Website https://www.roberts-ryan.com

December 22, 2022 09:30 AM Eastern Standard Time